Strokes Before 55 Nearly Doubled. Heart Attacks Went the Other Way
Cincinnati counted 2,076 first strokes in adults under 55: the rate rose from 34 to 62 per 100,000. In Oxford, young heart attacks fell over the same years.
Section
Body & Longevity
Health, longevity and biotech, read at the source. Biomarkers are tracked, but the verdict always waits for outcomes: events, function, years lived well.
Diet and Exercise Moved 16 Aging Clocks. Supplements Didn’t
A Yale analysis of 51 studies finds diet and exercise move aging clocks reliably, if modestly, while over the counter supplements barely register.
Deep Sleep and Alzheimer's: What Two New Studies Can and Can't Say
As tau builds in healthy older brains, deep sleep waves stop traveling and memory slips. A strong signal, but nobody yet knows which comes first.
Your Sleep Tracker Knows How Long You Slept. Not How Deeply
Every tracker in the lab studies could tell when people were asleep; none could reliably say how deeply, least of all in older adults and patients.
The First PCSK9 Pill Is Here. The Proof Still Comes From a Shot
A daily tablet now cuts LDL by more than half, while the injectable version of the same drug class was linked to 20% fewer deaths in people with no prior heart attack.
The Lp(a) Test Everyone Should Get Once, and What It Can't Tell You
One blood test for life sounds simple, but this year's research shows the result can move, the risk has no clean cutoff, and no Lp(a) drug has proven it saves hearts.
Retatrutide Takes Weight Off. Viking Bets a Monthly Shot Keeps It
Retatrutide's 20.8% assumes nobody quit, and Viking's 90% comes from a group of 11. The numbers behind the two biggest obesity drug headlines of September.
Myostatin Blockers Cut GLP-1 Muscle Loss. Strength Is Unproven
Trevogrumab and apitegromab saved kilograms of lean tissue in phase 2 trials, but no study has yet shown that it makes anyone stronger.
CagriSema and EloraTZP Both Beat Tirzepatide. Read the Doses
Novo won at the low end of the dose range, 12.4 versus 9.1 percent. Lilly won at the top, 23.3 versus 14.8, and lost up to one patient in four to side effects.
A GLP-1 Pill Against Insulin: What ACHIEVE-4 Proved for the Heart
Orforglipron cleared a heart safety bar against insulin glargine, 4.2 versus 5.0 percent, and posted a mortality gap the trial was never built to prove.
Lp(a): The Heart Risk Factor Science Still Can't Treat
Pelacarsen lowered the biomarker in 8,323 patients. Events did not follow. What that gap teaches about every longevity claim.
Biological Age Claims Need More Than One Clock
A Yale reanalysis of 12 epigenetic clocks says single clock drops don't reproduce. Then come the claims: GLP-1s, a skin cream, 2 to 3 years younger.
The Pill Duel: Orforglipron Beats Oral Semaglutide Head to Head
ACHIEVE-3, 1,698 adults, 52 weeks: in the primary analysis HbA1c fell 1.91 points against 1.47. A real head to head, run by one of the duelists.
Muscle Without Meat After 55: What the IMPACT Trial Found
Twelve weeks of lifting: vegetarians gained 0.38 kg of limb muscle, omnivores 0.66 kg. The trial could not show the two diets were equivalent.
Aprocitentan: Another Dial for Hard to Control Blood Pressure
Against placebo, the endothelin blocker lowered systolic pressure by about 4 mmHg on top of three drugs. New post hoc data on obesity and kidney risk.
The Race to Keep Muscle on GLP-1s Reaches Phase 2
Sironax's FORGE-LM trial is half enrolled. The endpoint is body composition, which is the right question. Enrollment, though, is not a result.
Your Body Clock Leaves a Signature on Your Wrist
809 adults, seven days of wrist sensors: robust temperature rhythms tracked with better metabolic markers, light with lower triglycerides. Association only.
The rule of this section
Not medical advice, ever. What a study measured, what it didn't, and who it was measured in, stated on the page. Preprints and press releases wear their labels until the peer reviewed paper exists.
Get Facts First, every Sunday
One email a week: the 5 facts that mattered in AI, health and longevity, each checked against the original source. No spam. Unsubscribe in one click.
By subscribing you agree to receive the newsletter. See the privacy policy.